Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimization of platelet therapy.

J A Fry1, C L Grines

  • 1Department of Cardiology, William Beaumont Hospital, Royal Oak, Michigan 48074, USA. jfry@smtpgw.beaumont.edu

Seminars in Interventional Cardiology : SIIC
|October 31, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A time-to-treatment analysis in the medicine versus angiography in thrombolytic exclusion (MATE) trial.

Journal of interventional cardiology·2002
Same author

Role of prolonged intravenous heparin in unstable angina patients prior to coronary angioplasty.

Journal of interventional cardiology·2002
Same author

Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction.

European heart journal·2002
Same author

One-year follow-up after primary coronary intervention for acute myocardial infarction in diabetic patients. A substudy of the STENT PAMI trial.

Arquivos brasileiros de cardiologia·2002
Same author

Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial.

Circulation·2001
Same author

Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial).

The American journal of cardiology·2001
Same journal

Atherectomy plus stenting: what do we gain?

Seminars in interventional cardiology : SIIC·2001
Same journal

The place of directional coronary atherectomy for the treatment of in-stent restenosis.

Seminars in interventional cardiology : SIIC·2001
Same journal

The place of rotablator for treatment of in-stent restenosis.

Seminars in interventional cardiology : SIIC·2001
Same journal

Directional coronary atherectomy: optimal atherectomy trials and new combined strategies with coronary stents.

Seminars in interventional cardiology : SIIC·2001
Same journal

Further insights into coronary debulking: the EUROCARE trial of directional atherectomy and the PACT trial of pullback atherectomy.

Seminars in interventional cardiology : SIIC·2001
Same journal

Morphological analysis of atherosclerotic plaque retrieved by coronary atherectomy.

Seminars in interventional cardiology : SIIC·2001
See all related articles

Adequate antiplatelet therapy, including newer potent agents alongside aspirin, is crucial for reducing ischemic complications after percutaneous coronary intervention and stenting.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Pharmacology

Background:

  • Percutaneous coronary intervention (PCI) causes vessel injury, leading to platelet activation and peri-procedural ischemic complications.
  • Historically, aspirin was the primary antiplatelet therapy post-PCI, with limited efficacy.
  • Recent advancements include more potent antiplatelet agents that significantly reduce ischemic events.

Purpose of the Study:

  • To highlight the critical role of antiplatelet therapy in mitigating PCI-related ischemic complications.
  • To discuss the evolution and impact of antiplatelet agents in interventional cardiology.

Main Methods:

  • Review of existing literature on antiplatelet therapies post-PCI.
  • Analysis of the benefits of aspirin and newer antiplatelet agents, including thienopyridines.

Related Experiment Videos

  • Evaluation of the impact of optimized antiplatelet regimens on coronary stenting outcomes.

    • Main Results:

    • Newer, potent antiplatelet agents demonstrate consistent reductions in ischemic events after PCI.
    • These agents provide an enduring protective effect against ischemic complications.
    • Optimized antiplatelet therapy with aspirin and thienopyridines has facilitated the widespread use of coronary stents.

    Conclusions:

    • Effective antiplatelet therapy is essential for managing patients undergoing PCI.
    • The development of potent antiplatelet agents represents a significant advancement in reducing peri-procedural ischemia.
    • Optimized antiplatelet strategies are key to the success of modern coronary stenting procedures.